अतिरिक्त कैलोरी के कारण मोटापा: जब जीवनशैली और व्यवहार चिकित्सा ने लक्षित वजन घटाने को प्राप्त नहीं किया हो तो क्या करें

DOI: 10.2337/dc26-S008

Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes.

In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.

Unless clinical circumstances (such as poor tolerability) or other considerations (such as financial expense or individual preference) suggest otherwise, those who achieve sufficient early weight loss upon starting a chronic obesity pharmacotherapy (typically defined as >5% weight loss after 3 months of use) should continue the medication long-term.

Upon initiating medications for obesity, assess their effectiveness and safety at least monthly for the first 3 months and at least quarterly thereafter.

View source ↗